BRIEF-Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved In China

July 23 (Reuters) - Haisco Pharmaceutical Group Co Ltd 002653.SZ:

  • HAISCO'S CLASS 1 INNOVATIVE DRUG CIPROCOPAN SUCCINATE TABLETS APPROVED IN CHINA, OFFERING A NEW TREATMENT OPTION FOR PATIENTS WITH PNH

  • HAISCO PHARMACEUTICAL GROUP CO - TO RECEIVE $40 MILLION UPFRONT, UP TO $1.42 BILLION IN MILESTONE PAYMENTS FOR HSK42360, HSK39297

  • HAISCO PHARMACEUTICAL GROUP CO - ELIGIBLE FOR TIERED ROYALTIES UP TO DOUBLE-DIGIT PERCENTAGES ON FUTURE SALES

Source text: ID:nPnQrsr2a

Further company coverage: 002653.SZ


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.